SCHEMBL17615519

SCHEMBL17615519

CC(C)(C)Nc1ccc(-c2ccc(CN)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.56
TAAR1 Q96RJ0 4/20 0.48
F9 P00740 2/20 0.40
CYP2A6 P11509 1/20 0.39
PSIP1 O75475 1/20 0.38
ADRB2 P07550 1/20 0.38
LOXL2 Q9Y4K0 3/20 0.38
LTA4H P09960 1/20 0.37
PLG P00747 2/20 0.37
KLK1 P06870 2/20 0.37
KLK6 Q92876 2/20 0.37
KLKB1 P03952 1/20 0.37
ABAT P80404 1/20 0.37
F11 P03951 1/20 0.36
F7 P08709 1/20 0.36
CYP2C9 P11712 1/20 0.36
AKT2 P31751 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10246718 0.94 HRH3 (0.44) HRH3TAAR1PSIP1LOXL2PLG
SCHEMBL25199389 0.88 HRH3 (0.39) HRH3TAAR1F9PSIP1LOXL2
SCHEMBL19088282 0.78 TAAR1 (0.56) TAAR1CYP2A6LOXL2
SCHEMBL17615518 0.77 ALDH1A1 (0.50) TAAR1CYP2C9
SCHEMBL17619352 0.77 HRH3 (0.64) HRH3TAAR1F9CYP2A6ADRB2
SCHEMBL13884337 0.76 LMNA (0.48)
SCHEMBL6248799 0.76 HPGD (0.45) TAAR1CYP2A6
SCHEMBL4603900 0.75 IDO1 (0.39) CYP2C9
SCHEMBL2274647 0.75 HRH3 (1.00) HRH3TAAR1CYP2A6ADRB2LOXL2
SCHEMBL27112966 0.74 HTR6 (0.46) LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10208035-B2 Compounds for inhibiting drug-resistant strains of HIV-1 integrase THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2019-02-19 US disclosed
US-20170305904-A1 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) 2017-10-26 US disclosed
US-20170305904-A1 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) 2017-10-26 US disclosed
US-9676771-B2 Compounds for inhibiting drug-resistant strains of HIV-1 integrase THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2017-06-13 US disclosed
US-9676771-B2 Compounds for inhibiting drug-resistant strains of HIV-1 integrase THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2017-06-13 US disclosed
US-20160083382-A1 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE The United States of American, as represented by the Sec, Dept. of Health and Human Services (US) 2016-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10208035-B2 Compounds for inhibiting drug-resistant strains of HIV-1 integrase CCR8, CDK8, CHD8 HRH3 30/4885TAAR1 1653/4885F9 196/4885
US-20170305904-A1 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE CCR8, CDK8, CHD8 HRH3 30/4885TAAR1 1653/4885F9 196/4885
US-20160083382-A1 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE CCR8, CDK8, CHD8 HRH3 30/4885TAAR1 1653/4885F9 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.